Alzheimer's Disease Long-term Follow-up Study (ALF Study)

NCT00165724 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2021-12-30

No results posted yet for this study

Summary

Open study for efficacy and safety of donepezil treatment during 48 weeks

Conditions

Interventions

DRUG

Donepezil Hydrochloride

Sponsors & Collaborators

  • Eisai Korea Inc.

    lead INDUSTRY

Principal Investigators

  • Jiheed Mun · Eisai Korea Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2006-07-31
Completion
2006-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165724 on ClinicalTrials.gov